Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
40
CHJTF Quote, Financials, Valuation and Earnings
Last price:
$0.95
Seasonality move
:
10.28%
Day range:
$0.95 - $0.95
52-week range:
$0.54 - $1.28
Dividend yield:
3.24%
P/E ratio:
20.50x
P/S ratio:
3.05x
P/B ratio:
8.34x
Volume:
--
Avg. volume:
168
1-year change:
46.37%
Market cap:
$10.9B
Revenue:
$4B
EPS (TTM):
$0.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHJTF
CSPC Pharmaceutical Group Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.18% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHJTF
CSPC Pharmaceutical Group Ltd.
|
$0.95 | -- | $10.9B | 20.50x | $0.02 | 3.24% | 3.05x |
|
ADAG
Adagene, Inc.
|
$1.82 | $9.22 | $85.7M | -- | $0.00 | 0% | 819.10x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.81 | $4.00 | $16.6M | -- | $0.00 | 0% | 0.47x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.41 | -- | $4.6M | -- | $0.00 | 0% | 1.14x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.04 | $49.49 | $2B | -- | $0.00 | 0% | 4.38x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHJTF
CSPC Pharmaceutical Group Ltd.
|
1.2% | 1.703 | -- | 1.93x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHJTF
CSPC Pharmaceutical Group Ltd.
|
$646.8M | $205.9M | 12.94% | 12.37% | 25.7% | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
CSPC Pharmaceutical Group Ltd. vs. Competitors
-
Which has Higher Returns CHJTF or ADAG?
Adagene, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital CHJTFCSPC Pharmaceutical Group Ltd.67.08% $0.02 $4.7B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About CHJTF or ADAG?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 406.83%. Given that Adagene, Inc. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Adagene, Inc. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHJTFCSPC Pharmaceutical Group Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is CHJTF or ADAG More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.280, which suggesting that the stock is 72.049% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CHJTF or ADAG?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 3.24%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 65.08% of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHJTF or ADAG?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Adagene, Inc. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Adagene, Inc.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 20.50x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.05x versus 819.10x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHJTFCSPC Pharmaceutical Group Ltd.3.05x 20.50x $964.2M $203.2M ADAGAdagene, Inc.819.10x -- -- --
-
Which has Higher Returns CHJTF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -353.92%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital CHJTFCSPC Pharmaceutical Group Ltd.67.08% $0.02 $4.7B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About CHJTF or CASI?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 393.83%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHJTFCSPC Pharmaceutical Group Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is CHJTF or CASI More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.280, which suggesting that the stock is 72.049% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock CHJTF or CASI?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 3.24%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 65.08% of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHJTF or CASI?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 20.50x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.05x versus 0.47x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHJTFCSPC Pharmaceutical Group Ltd.3.05x 20.50x $964.2M $203.2M CASICASI Pharmaceuticals, Inc.0.47x -- $3.1M -$10.9M
-
Which has Higher Returns CHJTF or CPHI?
China Pharma Holdings, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -86.16%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital CHJTFCSPC Pharmaceutical Group Ltd.67.08% $0.02 $4.7B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About CHJTF or CPHI?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHJTFCSPC Pharmaceutical Group Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is CHJTF or CPHI More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.280, which suggesting that the stock is 72.049% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock CHJTF or CPHI?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 3.24%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 65.08% of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHJTF or CPHI?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 20.50x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.05x versus 1.14x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHJTFCSPC Pharmaceutical Group Ltd.3.05x 20.50x $964.2M $203.2M CPHIChina Pharma Holdings, Inc.1.14x -- $756.2K -$651.5K
-
Which has Higher Returns CHJTF or SVA?
Sinovac Biotech Ltd. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CHJTFCSPC Pharmaceutical Group Ltd.67.08% $0.02 $4.7B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CHJTF or SVA?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHJTFCSPC Pharmaceutical Group Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CHJTF or SVA More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.280, which suggesting that the stock is 72.049% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock CHJTF or SVA?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 3.24%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. CSPC Pharmaceutical Group Ltd. pays 65.08% of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHJTF or SVA?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 20.50x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.05x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHJTFCSPC Pharmaceutical Group Ltd.3.05x 20.50x $964.2M $203.2M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CHJTF or ZLAB?
Zai Lab Ltd. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -30.98%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital CHJTFCSPC Pharmaceutical Group Ltd.67.08% $0.02 $4.7B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About CHJTF or ZLAB?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 174.33%. Given that Zai Lab Ltd. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Zai Lab Ltd. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHJTFCSPC Pharmaceutical Group Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is CHJTF or ZLAB More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.280, which suggesting that the stock is 72.049% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock CHJTF or ZLAB?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.02 per share corresponding to a yield of 3.24%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 65.08% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHJTF or ZLAB?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 20.50x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.05x versus 4.38x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHJTFCSPC Pharmaceutical Group Ltd.3.05x 20.50x $964.2M $203.2M ZLABZai Lab Ltd.4.38x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
